Aman Kansal MD , Pooja Swamy MD , Jennifer A. Rymer MD, MBA, MHS
{"title":"Dual Antiplatelet and Anticoagulation Regimens for Women Undergoing Percutaneous Coronary Intervention","authors":"Aman Kansal MD , Pooja Swamy MD , Jennifer A. Rymer MD, MBA, MHS","doi":"10.1016/j.iccl.2024.08.012","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":38721,"journal":{"name":"Interventional Cardiology Clinics","volume":"14 1","pages":"Pages 29-36"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Interventional Cardiology Clinics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211745824000956","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
接受经皮冠状动脉介入治疗的女性的双重抗血小板和抗凝治疗方案。
经皮冠状动脉介入治疗后的双重抗血小板疗法(DAPT)是预防支架血栓形成和确保长期心血管保护所必需的。在决定治疗方案和持续时间时,必须深思熟虑,平衡血栓和出血风险。血管重建随机试验已对许多特定的高危人群进行了研究,但女性患者的比例仍然偏低。虽然有证据支持缩短女性的 DAPT 持续时间,尤其是出血风险较高或长期口服抗凝药的女性,但我们需要专门针对女性进行试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。